Biote Corp. Class A Common Stock BTMD · Stock Open Biote Corp. Class A Common Stock in new tab
Biote Corp. Class A Common Stock Analysis (BTMD)
Is Biote Corp. Class A Common Stock a good investment? Biote Corp. Class A Common Stock (BTMD) is currently trading at 2.29 USD. Market analysts have a consensus price target of 2.73 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 5.23. This relatively low multiple may signal that Biote Corp. Class A Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Biote Corp. Class A Common Stock is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is 0.57.
Investor FAQ
Does Biote Corp. Class A Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Biote Corp. Class A Common Stock?
Biote Corp. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 0.39.
Company Profile
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Community Discussion